a growth of 16% on year-over-year and 4% Q-o-Q. This includes revenues from the acquired NRT business of Rs. 6,605 crores. Excluding NRT revenues, the underlying growth is at 7.5% on year-over ...

Global generics revenue grew 17% YoY to $850 million, with 7% growth excluding NRT contributions and a 1% rise in North American sales. Get real-time earnings alerts before the market moves and ...

Growth in mainstay global generics revenue was largely driven by revenues from the nicotine replacement therapy (NRT) portfolio, outside of the U.S., acquired from British consumer healthcare firm ...

The pharma major maintained that underlying YoY growth excluding NRT is 7.5% and a decline of 3% QoQ. According to the company, the growth was largely driven by revenues from the recently acquired ...

Dr. Reddy's stock falls on Q3 fiscal 2025 results, wherein earnings match estimates but revenues beat the same.

The increase was primarily driven by revenues from the recently acquired Nicotine Replacement Therapy (NRT) portfolio, higher volumes and new product launches. Dr. Reddy’s launched four new ...

Hyderabad: Despite posting record revenues, pharma major Dr Reddy's Laboratories on Thursday reported a marginal 2% increase in consolidated profit after tax (PAT attributable to equity holders) at 1, ...

The Trustees of North European Oil Royalty Trust (NYSE-NRT) announced today a quarterly distribution of $0.04 per unit ...

The Co-Chairman & MD, G V Prasad said that company's double-digit growth was aided by its newly acquired NRT business, new launches and improved operational efficiencies. "We remain committed to ...

This isn't an entry-level setup. It includes many of Samsung's high-end tech, including Q Symphony and Dynamic Sound. By Stan Horaczek Posted on Jan 21, 2025 We may earn revenue from the products ...

Indian pharmaceutical (IT) major, Dr Reddy's Laboratories, is scheduled to deliver its October-December quarterly earnings for the financial year 2024-25 (Q3FY25) on Thursday, January 23, 2025 ...